lapatinib - Ontology Report - Rat Genome Database

lapatinib results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101 PMID:28437613

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

Abcb1a

ATP binding cassette subfamily B member 1A

multiple interactions

lapatinib inhibits the reaction [ABCB1 protein results in increased export of and results in decreased susceptibility to Doxorubicin]; lapatinib inhibits the reaction [azidoprazosin binds to ABCB1 protein]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]

PMID:18829547

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

Abcb4

ATP binding cassette subfamily B member 4

decreases activity

lapatinib results in decreased activity of ABCB4 protein

PMID:28437613

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

Abcg2

ATP binding cassette subfamily G member 2

multiple interactions

lapatinib inhibits the reaction [ABCG2 gene mutant form results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Topotecan]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; lapatinib inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]; lapatinib inhibits the reaction [azidoprazosin binds to ABCG2 protein]; lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]

PMID:18829547

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

Acta2

actin alpha 2, smooth muscle

multiple interactions

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

Akt1

AKT serine/threonine kinase 1

multiple interactions
decreases expression
decreases activity
decreases phosphorylation

[Bortezomib co-treated with Lapatinib] results in decreased phosphorylation of AKT1 protein; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of AKT1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]
lapatinib results in decreased expression of AKT1 protein; lapatinib results in decreased expression of AKT1 protein modified form
lapatinib results in decreased activity of AKT1 protein
Lapatinib results in decreased phosphorylation of AKT1 protein

PMID:15665275 PMID:16091755 PMID:19435893 PMID:19509167 PMID:20701607 More...

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

Aldh1a1

aldehyde dehydrogenase 1 family, member A1

multiple interactions

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ALDH1A1 protein

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

Bax

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

Lapatinib results in increased expression of BAX protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased expression of BAX protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]]

PMID:29387217 PMID:32890875

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

Bcl2

BCL2, apoptosis regulator

decreases expression
multiple interactions

Lapatinib results in decreased expression of BCL2 protein
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]

PMID:29387217 PMID:32890875

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

Birc5

baculoviral IAP repeat-containing 5

decreases expression

lapatinib results in decreased expression of BIRC5 protein

PMID:16091755

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

Bnip3

BCL2 interacting protein 3

multiple interactions

Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA]

PMID:25981168

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

Casp3

caspase 3

increases cleavage
multiple interactions

Lapatinib results in increased cleavage of CASP3 protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP3 protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]

PMID:29387217 PMID:32890875

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

Casp9

caspase 9

multiple interactions
increases cleavage

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP9 protein]

PMID:29387217

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

Ccna2

cyclin A2

decreases expression

lapatinib results in decreased expression of CCNA2 protein

PMID:25221644

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

Ccnd1

cyclin D1

multiple interactions
decreases expression

2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]; [afimoxifene co-treated with Lapatinib] results in decreased expression of CCND1 protein; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]
lapatinib results in decreased expression of CCND1 protein

PMID:15665275 PMID:25221644 PMID:32890875 PMID:33396024

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

Ccne1

cyclin E1

multiple interactions

[afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]

PMID:15665275

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

Cd24

CD24 molecule

multiple interactions

[lapatinib results in decreased susceptibility to lapatinib] which results in decreased expression of CD24 protein

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

Cd44

CD44 molecule (Indian blood group)

multiple interactions

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CD44 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]]

PMID:26643609 PMID:33396024

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

Cdh1

cadherin 1

multiple interactions

[Genistein co-treated with Lapatinib] promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein]

PMID:26643609 PMID:32890875 PMID:33396024

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

Cdh2

cadherin 2

multiple interactions

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein]

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

Cdk2

cyclin dependent kinase 2

multiple interactions

PMID:15665275

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

Cdkn1a

cyclin-dependent kinase inhibitor 1A

multiple interactions

Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

Cdkn1b

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression

[afimoxifene co-treated with Lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; [afimoxifene co-treated with Lapatinib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]
lapatinib results in increased expression of CDKN1B protein

PMID:15665275 PMID:20701607 PMID:32890875

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

Cyp1a1

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

Lapatinib results in decreased activity of CYP1A1 protein

PMID:33814510

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

Cyp1b1

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Lapatinib results in decreased activity of CYP1B1 protein

PMID:33814510

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

Cyp3a2

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing
multiple interactions

CYP3A4 protein results in increased metabolism of Lapatinib
[CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of HMOX1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of NQO1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD2 mRNA

PMID:26958860 PMID:33259822

NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008

Cyp3a9

cytochrome P450, family 3, subfamily a, polypeptide 9

increases metabolic processing
multiple interactions

CYP3A5 protein results in increased metabolism of lapatinib
[CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

Egfr

epidermal growth factor receptor

decreases activity
multiple interactions
affects response to substance

lapatinib results in decreased activity of EGFR protein
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]; lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]

PMID:15665275 PMID:17192538 PMID:19509167 PMID:20549698 PMID:28739874

NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382

Erbb2

erb-b2 receptor tyrosine kinase 2

multiple interactions
decreases activity
decreases expression
decreases phosphorylation

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of ERBB2 protein; Bortezomib promotes the reaction [Lapatinib results in decreased phosphorylation of ERBB2 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of MCM7 protein]; Lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]
lapatinib results in decreased activity of ERBB2 protein
lapatinib results in decreased expression of ERBB2 protein
lapatinib results in decreased phosphorylation of ERBB2 protein

PMID:15665275 PMID:16091755 PMID:17192538 PMID:19509167 PMID:20197467 More...

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

Erbb3

erb-b2 receptor tyrosine kinase 3

decreases expression
decreases activity

lapatinib results in decreased expression of ERBB3 protein modified form
lapatinib results in decreased activity of ERBB3 protein

PMID:19435893 PMID:19509167

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

Esr1

estrogen receptor 1

decreases activity
multiple interactions

lapatinib results in decreased activity of ESR1 protein
[lapatinib co-treated with afimoxifene] results in decreased activity of ESR1 protein

PMID:15665275

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

Gpt

glutamic--pyruvic transaminase

increases secretion

Lapatinib results in increased secretion of GPT protein

PMID:29655783

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

Hif1a

hypoxia inducible factor 1 subunit alpha

multiple interactions

PMID:25981168 PMID:32890875

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

Hmox1

heme oxygenase 1

multiple interactions
increases expression

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of HMOX1 mRNA
lapatinib metabolite results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

Jak2

Janus kinase 2

multiple interactions

Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of JAK2 protein]

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

Kras

KRAS proto-oncogene, GTPase

decreases response to substance
multiple interactions

KRAS protein results in decreased susceptibility to lapatinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]

PMID:28739874

NCBI chr 4:178,185,418...178,218,484

Mapk1

mitogen activated protein kinase 1

multiple interactions
decreases activity
decreases expression
decreases phosphorylation

ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]
lapatinib results in decreased activity of MAPK1 protein
lapatinib results in decreased expression of MAPK1 protein
lapatinib results in decreased phosphorylation of MAPK1 protein

PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

Mapk12

mitogen-activated protein kinase 12

multiple interactions

lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]

PMID:28739874

NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664

Mapk3

mitogen activated protein kinase 3

multiple interactions
decreases activity
decreases expression
decreases phosphorylation

ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]
lapatinib results in decreased activity of MAPK3 protein
lapatinib results in decreased expression of MAPK3 protein
lapatinib results in decreased phosphorylation of MAPK3 protein

PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

Mcm7

minichromosome maintenance complex component 7

multiple interactions
decreases expression

ERBB2 protein affects the reaction [lapatinib results in decreased expression of MCM7 protein]

PMID:25221644

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

Mtor

mechanistic target of rapamycin kinase

multiple interactions

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

Nfe2l2

NFE2 like bZIP transcription factor 2

multiple interactions
increases activity

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein
lapatinib metabolite results in increased activity of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737

Nqo1

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of NQO1 mRNA
lapatinib metabolite results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

Parp1

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of PARP1 protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]; [Lapatinib co-treated with bafilomycin A] results in increased cleavage of PARP1 protein; [Lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein; Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]

PMID:25221644 PMID:25981168 PMID:29387217 PMID:32890875

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

Pcna

proliferating cell nuclear antigen

multiple interactions

2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]

PMID:32890875 PMID:33396024

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

Ptgs2

prostaglandin-endoperoxide synthase 2

multiple interactions

NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188

Ptpn3

protein tyrosine phosphatase, non-receptor type 3

multiple interactions

lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]

PMID:28739874

NCBI chr 5:71,908,520...72,027,323
Ensembl chr 5:71,911,135...72,065,443

Raf1

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions

Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of RAF1 protein]

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

Rb1

RB transcriptional corepressor 1

multiple interactions

Lapatinib inhibits the reaction [sodium arsenite results in decreased phosphorylation of RB1 protein]

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

Rela

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

Snai1

snail family transcriptional repressor 1

multiple interactions
decreases response to substance

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of SNAI1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein]
SNAI1 protein results in decreased susceptibility to lapatinib

PMID:26643609 PMID:32890875 PMID:33396024

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

Snai2

snail family transcriptional repressor 2

multiple interactions

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]]

PMID:33396024

NCBI chr11:86,183,800...86,186,109
Ensembl chr11:86,181,909...86,186,200

Sod1

superoxide dismutase 1

multiple interactions

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

Sod2

superoxide dismutase 2

multiple interactions
increases expression

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD2 mRNA
lapatinib metabolite results in increased expression of SOD2 mRNA

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

Sox2

SRY-box transcription factor 2

multiple interactions

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of SOX2 protein

NCBI chr 2:117,536,929...117,539,338
Ensembl chr 2:117,536,929...117,539,338

Src

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of SRC protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein]

PMID:26643609 PMID:32890875

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

Stat3

signal transducer and activator of transcription 3

multiple interactions

Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of STAT3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of STAT3 protein]

PMID:32890875 PMID:33396024

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

Tgfb1

transforming growth factor, beta 1

decreases response to substance

TGFB1 protein results in decreased susceptibility to lapatinib

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

Twist1

twist family bHLH transcription factor 1

multiple interactions

Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]]

PMID:33396024

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653

Ugt1a2

UDP glucuronosyltransferase 1 family, polypeptide A2

decreases activity
multiple interactions

Lapatinib results in decreased activity of UGT1A3 protein
[Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of obeticholic acid; [Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of Ursodeoxycholic Acid

PMID:31299240

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

Vegfa

vascular endothelial growth factor A

multiple interactions

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

Vim

vimentin

multiple interactions

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VIM protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein]